Presentation is loading. Please wait.

Presentation is loading. Please wait.

Types Selection Complications

Similar presentations

Presentation on theme: "Types Selection Complications"— Presentation transcript:

1 Types Selection Complications
Prosthetic valves Types Selection Complications

2 Types Bioprosthetic valves Mechanical Heterograft (xenograft)
Bovine porcine Homograft (allograft) Autograft Pericardial Pulmonary (Ross) Mechanical Caged ball valve Tilting disc valve Bileaflet valve

3 Heterografts(xenografts)
The Hancock M.O. II aortic bioprosthesis (porcine) Stentless Porcine Toronto SPV valve, medtronic freestyle valve Stented - facilitate implant, maintain 3D relationship,more physiological flow Hancock , carpenteir edward s, medtronic Bovine Stented bovine p prosthesis Carpentier-Edwards Duralex mitral bioprosthesis

4 Tissue heterograft Advantages Disadvantages
- No need of anticoagulation after 1st 3 m Little hemolysis Disadvantages Limited ,uncertain durability Cuspal tear Perforation degeneration Rapid deterioration esp children Fibrin depostn Ca++ 10-30% need re op in 10 yr 30-60% need re op in 15 yr Small size have poor hemodynamics

5 Bioprosthetic valve Preferred in Pregnancy Bleeding Diathesis
Age> 70 years Poor compliance

6 Mechanical valves Caged ball valve Advantages Disadvantages
Oldest durabilty upto 40 yr Disadvantages high profile hemolysis high thrombogenecity Poor hemodynamics in small sizes Unique features Occluder travels completely out of the orifice, reduces thrombus & pannus growing from the sewing ring Continuously changing points of contact of the ball reduces the wear & tear in any one area Thrombogenic risk 4-6% / year

7 Starr Edwards Valve not suitable
- for the mitral position in patients with a small left ventricular cavity - for the aortic position in those with a small aortic annulus - those requiring a valve-aortic arch composite graft

8 Tilting disc valve- monoleaflet
- Medtronic Hall valve - Omnicarbon (Medical CV) - Monostrut (Alliance Medical Technologies) - Bjork-Shiley valves Adv low profile Good hemodynamics even in small sizes Excellent durability Permit central laminar flow Medtronic hall valve Titanium housing teflon sewing ring carbon coated disc disadv – Anticoagulation mandatory higher risk of thrombosis than cage ball v sudden catastrophic valve thrombosis

9 Bileaflet valve Adv – Anticoagulation mandatory risk of thrombosis
St. Jude Medical mechanical heart valve Bileaflet valve Adv – Low bulk - flat profile Less thrombogenicy Central laminar flow two semicircular discs that pivot between open and closed positions No need for supporting struts Good hemodynamics even in small sizes 2 lat ,1 central minor orifice , no chance of sudden catastro thrombosis Disadv- Anticoagulation mandatory risk of thrombosis Carbomedics Titanium housing Pyrolytic carbon


11 Model Thrombogenicity
Types of prosthetic valves and thrombogenicity Type of valve Model Thrombogenicity Mechanical Caged ball Starr-Edwards ++++ Single tilting disc Bjork-Shiley,Medtronic Hall +++ Bileaflet St Jude Medical,Sorin Bicarbon,Carbomedics ++ Bioprosthetic Heterografts Carpentier-Edwards,Tissue Med (Aspire), Hancock II + to ++ Homografts +

12 TTK chitra tilting disc valve
- metallic housing (cobalt based wrought alloy) - circular disc high molecular weight polyethylene - A polyester suture ring Hemodynamically comparable to other mechanical valves valve related complications are similar


14 Characteristics of Various prosthetic valves

15 Flow Dynamics

16 Desired valves Mechanical valves - preferred in young patients
who have a life expectancy of more than 10 to 15 years who require long-term anticoagulant therapy for other reasons (e.g., atrial fibrillation) Bioprosthetic valves preferred in patients who are elderly have a life expectancy of less than 10 to 15 years who cannot take long-term anticoagulant therapy A bileaflet-tilting-disk or homograft prosthesis is most suitable for a patient with a small valvular annulus in whom a prosthesis with the largest possible effective orifice area is desired.

17 algorithm for choice of prosthetic heart valve


19 Radiologic Identification
Starr-Edwards caged ball valve Radiopaque base ring Radiopaque cage Three struts for the aortic valve; 4 struts for the mitral or tricuspid valve Silastic ball impregnated with barium that is mildly radiopaque (but not in all models)

20 TTE – stenosis Valve area calculations Continuity equation Area Ao prosthesis = (diameter sewing ring)² x 0.785xLVOT VTI/ Ao prosthesis VTI Area mitral prosthesis= (diameter LVOT)²x 0.785xLVOT VTI/ VTI mitral prosthesis Pressure Half time ( mitral valve prosthesis) Dimensionless index- LVOT velocity/ aortic prosthesis velocity < 0.23 indicates prosthetic valve stenosis

21 Prosthetic Valve regugitation
Mitral – velocity2.5m/sec - jet area 2cm² Aortic aortic PHT≤ 250m/sec -- flow reversal in aorta

22 Normal Doppler Values of Prosthetic Valves
Aortic Position Mitral Position Velocity Mean Gr Starr Edward 3.1±0.5 24±4 St Jude 3.0±0.8 11±6 Medtronic Hall 2.6±0.3 12±3 Aortic Homograft 0.8±0.4 7±3 Hancock 2.4±0.4 11±2 Carpentier’s 2.4±0.5 14±6 Velocity MeanGr Starr Edward ± ±2 St Jude ± ±2 Medtronic Hall ± ±2 Aortic Homograft 1.5± ±2 Hancock ± ±2 Carpentier’s ± ±2

23 Importance of TEE higher-resolution image than TTE
size of vegetation defined more precisely peri annular complications indicating a locally uncontrolled infection (abscesses, dehiscence, fistulas) detected earlier limitation -inability to detect aortic prosthetic-valve obstruction or regurgitation, especially when a mitral prosthesis is present

24 Mitral Bileaflet

25 Cinefluoroscopy Structural integrity Motion of the disc or poppet
excessive tilt ("rocking") of the base ring - partial dehiscence of the valve Aortic valve prosthesis - RAO caudal - LAO cranial Mitral -- RAO cranial

26 Fluoroscopy of a normally functioning CarboMedics bileaflet prosthesis in mitral position
A=opening angle B=closing angle

27 St. Jude medical bileaflet valve
Mildly radiopaque leaflets are best seen when viewed on end Seen as radiopaque lines when the leaflets are fully open Base ring is not visualized on most models

28 MRI Not useful in assessing prosthetic-valve structure
used only when prosthetic-valve regurgitation or para valvular leakage is suspected but not adequately visualized by echocardiography

29 Cardiac Catheterization
measure the transvalvular pressure gradient, from which the EOA can be calculated can visualize and quantify valvular or paravalvular regurgitation

30 Valve dysfunction complication example Role of echo
Primary mechanical failure Ball variance Strut fracture Visualize structure, assess gradient & regurgitation Nonstructural dysfunction Pt- prosthesis mismatch pannus Gradient, visualize tissue in & around the sewing ring Bleeding event Intracranial hge Source of embolus, presence & mobility of masses Endocarditis Vegetation, abcess, dehiscence Visualize area around the sewing ring, echo dense / lucent area, perivalvular regurgitation Thrombosis Thrombus impedes opening &closing of occluder mechanism Localize mass, assess gradient, detect regurgitation Embolism stroke Identify & characterize the source of emboli

31 patient-prosthesis mismatch
When the effective prosthetic valve area, after insertion into the patient less than that of a normal valve (Rahimtoola in 1978) EOA indexed to BSA is less than 0.85 cm2/m2 EOA (echo) differs from geometric orifice area (measured directly) EOA for each prostheses type & size obtained in literature from pts normally functioning prostheses Average if > 1 value -- mild ( cm² /m² -- moderate ( cm2/m² -- severe (iEOA < 0.6cm²/m² (Rahimtoola)

32 in-vitro area of the majority of valve prostheses ( int diameter <23 mm) < that of the normal human valve area the in-vivo prosthetic area further reduced by IVS hypertrophy, progressive endothelialization and tissue ingrowth (Aortic prosthetic devices may be functionally stenotic)

33 three-step algorithm Step 1: Calculation of the patient BSA.
Step 2: Reference to the specific table for identification of the adequate valvular EOA according to the patient BSA. Step 3: Selection of the most appropriate type and size of valve prosthesis according to the target iEOA


35 Valve Thrombosis <0.2% per year for mech valves
Incidence of 0.1 to 5.7 % per patient-year <0.2% per year for mech valves <0.1% bioprosthetic valves small thrombus, at the hinge portion of a bileaflet valve obstruct the mechanism tilting disk -- a much larger thrombus to prevent function Ball and cage valves – less susceptible  occluder has no contact at all with the valve housing for a portion of every cycle Clinical Non obstructive- incidental/embolic phenomenon Partial obstruction- dyspnea,systemic embolism , fever Severe obstruction- overt heart failure

36 Fibrinolytic therapy - Rt sided thrombosis 80-100% success rate
Surgery for fibrinolysis failure/symptoms > 3 wk Surgery – Lt sided thrombosis, large clot burden

37 FIBRINOLYTIC PROTOCOL heart 2007;93:137-142
2 types of protocol -rescue fibrinolysis (short protocol for unstable pt) - long protocol for stable pt Short protocol - r tPA 10 mg bolus + 90 mg in 90 min or - SK 15lac in 60 min Long protocol -- SK- 5lac u in 20 min f/b 15lac u for 10 hr -- rtPA mgbolus f/b 90mg/hr for 9 hrs Urokinase High dose: 4,500 IU/kg/h for 12 h without heparin Low dose: 2,000 IU/kg/h with heparin for 24 h



40 Embolisation cerebral embolization  CT normal/infarctwarf & heparin – 72 hrs APTT lower therapeutic level till the desired INR anticoagulantion delayed for at least 7 to 14 days - ICH, extensive cerebral infarction  OAC

41 If embolic event occurs while the patient is on adequate antithrombotic therapy
If on warfarin with INR of 2.0 to 3.0: increase dose to achieve INR of 2.5 to 3.5 If on warfarin with INR of 2.5 to 3.5: add aspirin 50 to 100 mg/d If on warfarin with INR of 2.5 to 3.5, plus aspirin 80 to 100 mg/d: aspirin dose may also need to be increased to 325 mg/d If on aspirin 325 mg/d: switch to warfarin with goal INR of 2.0 to 3.0

42 Excessive Anticoagulation
vit K 2.5 mg daily until the INR is acceptable fresh frozen plasma Human recombinant factor VIIa, 15 to 19 g/kg (INR >10.0 with bleeding)

43 Structural Failure of Bioprosthetic Valves
About 30 % of heterograft bioprosthetic valves and 10 to 20 % of homograft valves require replacement within 10 to 15 years because of structural failure severe regurgitation due to a tear or rupture of one or more of the valve cusps calcified and rigid valves Rarely severe valvular stenosis

44 Structural deterioration
Higher incidence patients <40 years & with mitral prostheses gradual onset of dyspnea and other symptoms of heart failure Bioprosthetic-valve regurgitation or stenosis can be detected by auscultation valve dysfunction assessed by echocardiography or catheterization

45 Failure of Bio prosthetic Valves

46 Hemolysis Incidence - 6% Subclinical intravascular hemolysis
severe hemolytic anemia uncommon & suggests paravalvular leakage due to partial dehiscence of the valve or infection Patients with a caged-ball valve / multiple prosthetic valves have an increased incidence & severity of hemolysis.

47 Hemolysis Pts with hemolytic anemia treated with iron & folate supplements or blood transfusion - decreased blood viscosity & increased COP a/w anemia increase the hemolysis Paravalvular leakage & severe hemolysis – valve replacement or repair

48 Para valvular leak improper implantation of a valve A heavily calcified annulus is a risk factor for paravalvular leaks -- incomplete debridement of calcium compromises both suture placement and valve seating Active endocarditis is also a risk factor Late paravalvular leaks are suggestive of prosthetic valve endocarditis generally result in hemolysis In the absence of a paravalvular leak, a normally functioning modern valve should not result in hemolysis

49 Paravalvular Regurgitation
mild or moderate paravalvular leakage - asymptomatic , may have only a mild hemolytic anemia - can be observed carefully with serial echo severe paravalvular leakage - usually have symptoms of heart failure or severe anemia - should be treated with surgical repair or replacement of the valve

50 PVE (2-6%) salient features
Endovascular, microbial infection occurring on parts of a valve prosthesis or on reconstructed native heart valves , with or without implantation of an annular ring early PVE is 5% higher in surgery during active IE Diagnostic approach, surgical indications same

51 PVE how diff from native? PVE NVE
Early- nosocomial Late- comm acquired Mech prosthesis -originate from the sewing cuff /from nearby located thrombi → periprosthetic leaks, ring abscesses, invasion of adjacent tissue Bioprosthesis infections mostly restricted to the cusps → secondary bioprosthetic failure Staphylococci, HACEK group, fungi occur more frequently in PVE Strepto & enterococci found more frequently in native valve endocarditis

52 vegetations larger irreversible adhesion production of a biofilm,  inhibit the host defence mechprotects against antimicrobial Tt Duration of Tt longer Smaller No such biofilm

53 Pannus Valve obstruction occurs 5-10% of mechanical valves per year
Thrombus Pannus mobile, somewhat less echo-dense, associated with spontaneous contrast Pannus formation -more common in aortic position fibrous tissue ingrowth highly echogenic usually firmly fixed to the valve apparatus Pre valve jet suggests pannus



56 MCQ

57 1. Factors favouring bioprostheses include all except a
1.Factors favouring bioprostheses include all except a. Age > 70 yrs b. Bleeding diathesis c. Combined multivalvular placement d. Poor compliance

58 2. Which of the following favours valve repair. a. RHD b
2. Which of the following favours valve repair? a. RHD b. Endocarditis c. Extensive leaflet destruction d. MVP

59 3. Which is the most durable mechanical prosthesis. a
3. Which is the most durable mechanical prosthesis? a. St Jude medical b. Medtronic Hall c. Starr- Edwards d. Bjork Shiley

60 4. Indication for long term anticoagulation in aortic bioprosthesis include all except a. Prior embolic events b. Atrial fibrillation c. Ventricular tachycardia d. LV dysfunction

61 5. 55yr male, s/p AVR for BAV , SR, good LV function, Dental prophylaxis needed, anti thrombotic therapy would be the following Stop warf 72 hrs before procedure, restart after control of bleeding Stop warf 72 hrs before procedure, start heparin 48hrs before procedure Stop warf 1wk before procedure d. Continue warf

62 6 . Heparin alone regimen in a pregnant lady on OAC, s/p MVR , thrombo embolic complications would be 25% 33% 43% 45%

63 7. Ideal anti thrombotic therapy in a 45 yr female, s/p MVR for RHD, with h/o embolic stroke would be the following Warfarin INR , aspirin mg Warfarin INR , aspirin mg Warfarin INR , aspirin mg Warfarin INR , aspirin mg

64 8. Prosthetic valve thrombosis would be catastrophic in the following
Bioprosthesis Tilting disc valve Bileaflet valve Starr- Edwards valve

65 9. Mitral prostheses best assessed by
RAO cranial RAO caudal LAO cranial LAO caudal

66 10. Clinical hemolysis is maximum with
Caged ball Bioprosthesis Tilting disc Bileaflet

Download ppt "Types Selection Complications"

Similar presentations

Ads by Google